J.P. Morgan Maintains Overweight on BioMarin Pharmaceuticals (BMRN)

J.P. Morgan is out with its report today on BioMarin Pharmaceuticals BMRN, maintaining Overweight. In a note to clients, J.P. Morgan writes, "After market close, BMRN reported a generally in-line quarter that contained few surprises. Overall, management's update was pretty quiet as the company's key pipeline programs are on track. We continue to believe that BMRN is well positioned and offers a nice blend of commercial value and pipeline optionality. Maintain OW." J.P. Morgan maintains a $32 PT on BMRN. Shares of BMRN closed Thursday at $26.46, down 1.31% from Wednesday's close.